Barclays lowered the firm’s price target on DaVita (DVA) to $160 from $169 and keeps an Equal Weight rating on the shares post the Q2 report. The firm says DaVita’s treatment growth and revenue per treatment were revised down as cyberattack disruptions drove higher missed treatment rates and revenue cycle challenges.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DVA: